Two cycles of dual neoadjuvant immunotherapy (nivolumab/ipilimumab or nivolumab/relatlimab) induced high pathological ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

The median event-free survival was not reached in the durvalumab arm and was 46.1 months in the control arm. Incorporating ...

Virologist treats breast cancer with oncolytic virotherapy, shrinking the tumor and boosting immune response. An ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially administered as an alternative treatment for patients not suitable for primary debulking surgery (PDS) because of unresectable ...

Sai-Lan Liu and colleagues 4 conducted a single-centre, phase 2 study comparing neoadjuvant and adjuvant administration of the PD-1 inhibitor, toripalimab, versus placebo in combination with ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound ...

Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure ...